Tiếng Việt
CIMT is Europe’s largest non-profit scientific event dedicated to cancer immunotherapy, attracting over 1,000 experts from more than 30 countries. CIMT 2025 featured scientific presentations, poster sessions, and in-depth exchanges on cutting-edge topics such as novel antigen discovery, cell therapies, immune monitoring, and the application of artificial intelligence.
At the conference, Dr. Loc presented a research poster titled:“Lynch Syndrome in a mCRC patient: A case of Extended Survival with Immuno-Oncology; what is the optimal duration as fourth line treatment.”
Through this study, Dr. Loc and his colleagues shared their experience using immunotherapy to treat a patient with metastatic colorectal cancer and Lynch syndrome. The report also raised important questions for discussion among cancer immunotherapy experts about determining the optimal timing for treatment at the fourth-line stage—following three prior systemic regimens that included various chemotherapies and targeted therapies—aiming to strike a balance between treatment effectiveness and the patient’s quality of life.
Dr. Loc shared:“Presenting at a prestigious conference like CIMT is a valuable opportunity for us to share practical treatment experiences and stay updated on the latest advancements in cancer immunotherapy. I hope the insights and knowledge gained from the conference will help improve cancer treatment outcomes in Vietnam.”
Participation and contributions at international forums like CIMT reflect HFH and its Oncology Unit’s commitment to global knowledge exchange, continuous advancement in treatment quality, and a patient-centered approach in all aspects of care.
